METRNL: A Double-Stranded RNA Protein with Potential as A Drug Target Or Biomarker

Target Name: METRNL

NCBI ID: G284207

METRNL

METRNL: A Double-Stranded RNA Protein with Potential as A Drug Target Or Biomarker

METRNL (METRNL variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-protein hybrids, known as double-stranded RNA viruses (dsRVs ), and is characterized by its unique structure and biological properties.

One of the most interesting aspects of METRNL is its potential as a drug target or biomarker. The use of small molecules to modulate the activity of METRNL has been shown to be an effective way to study its function and to identify new therapeutic approaches.

METRNL is a protein that is involved in the regulation of gene expression, and its function is critical for the development, maintenance, and progression of various diseases. Studies have shown that METRNL plays a key role in the regulation of inflammation, neurodegeneration, and cancer.

One of the potential reasons for the interest in METRNL is its unique structure, which allows it to interact with other proteins in a variety of ways. METRNL has a double-stranded RNA structure, and this allows it to form a complex with various proteins, including transcription factors, which can modulate its expression levels.

In addition, METRNL has been shown to play a role in the regulation of cellular processes that are important for the development and progression of diseases. For example, METRNL has been shown to be involved in the regulation of cell adhesion, which is critical for the development of cancer.

Another potential reason for the interest in METRNL is its role in the regulation of cellular signaling pathways. METRNL has been shown to play a key role in the regulation of the JAK/STAT signaling pathway, which is involved in the regulation of cellular processes that are important for the development and progression of many diseases, including cancer.

In conclusion, METRNL is a protein that is characterized by its unique structure and its role in the regulation of various cellular processes that are important for the development and progression of diseases. Its potential as a drug target or biomarker makes it an attractive target for the development of new therapeutic approaches. Further research is needed to fully understand the function of METRNL and its potential as a therapeutic approach.

Protein Name: Meteorin Like, Glial Cell Differentiation Regulator

Functions: Hormone induced following exercise or cold exposure that promotes energy expenditure. Induced either in the skeletal muscle after exercise or in adipose tissue following cold exposure and is present in the circulation. Able to stimulate energy expenditure associated with the browning of the white fat depots and improves glucose tolerance. Does not promote an increase in a thermogenic gene program via direct action on adipocytes, but acts by stimulating several immune cell subtypes to enter the adipose tissue and activate their prothermogenic actions. Stimulates an eosinophil-dependent increase in IL4 expression and promotes alternative activation of adipose tissue macrophages, which are required for the increased expression of the thermogenic and anti-inflammatory gene programs in fat. Required for some cold-induced thermogenic responses, suggesting a role in metabolic adaptations to cold temperatures (By similarity)

The "METRNL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METRNL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets